Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial.

[1]  D. Bluemke,et al.  Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). , 2013, Journal of the American College of Cardiology.

[2]  M. Shong,et al.  Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes , 2012, Diabetes.

[3]  M. Pirmohamed,et al.  Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists , 2012, PloS one.

[4]  A. Miras,et al.  Mechanisms of Weight Loss, Diabetes Control and Changes in Food Choices After Gastrointestinal Surgery , 2012, Current Atherosclerosis Reports.

[5]  F. Rubino,et al.  Bariatric surgery versus conventional medical therapy for type 2 diabetes. , 2012, The New England journal of medicine.

[6]  S. Litwin,et al.  Reductions in cardiovascular risk after bariatric surgery , 2011, Current opinion in cardiology.

[7]  E. Serné,et al.  Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review. , 2011, Archives of surgery.

[8]  Seth L Masters,et al.  The Inflammasome in Atherosclerosis and Type 2 Diabetes , 2011, Science Translational Medicine.

[9]  Denis Gris,et al.  Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling , 2011, Nature Immunology.

[10]  G. Bing,et al.  PPARα agonist prevented the apoptosis induced by glucose and fatty acid in neonatal cardiomyocytes , 2011 .

[11]  S. Hunt,et al.  Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. , 2011, Journal of the American College of Cardiology.

[12]  B. Cheung.  The hypertension-diabetes continuum. , 2010, Journal of cardiovascular pharmacology.

[13]  Wei Zhang,et al.  The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis , 2009, BMC public health.

[14]  M. Febbraio,et al.  Interleukin-6 Attenuates Insulin-Mediated Increases in Endothelial Cell Signaling but Augments Skeletal Muscle Insulin Action via Differential Effects on Tumor Necrosis Factor-α Expression , 2009, Diabetes.

[15]  T. Demir,et al.  A possible new risk factor in diabetic patients with erectile dysfunction: homocysteinemia. , 2008, Journal of diabetes and its complications.

[16]  D. Giannessi,et al.  Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. , 2007, Pharmacological research.

[17]  X. Zhang,et al.  Homocystinemia as an Independent Risk Factor in the Chinese Population at a High Risk of Coronary Artery Disease , 2007 .

[18]  R. Wachter,et al.  Impact of diabetes on left ventricular diastolic function in patients with arterial hypertension , 2007, European journal of heart failure.

[19]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[20]  E. Eschwège,et al.  Evaluation of risk factors for development of complications in Type II diabetes in Europe , 2002, Diabetologia.

[21]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.